Rivaroxaban Plus Aspirin Reduces Adverse Events After Revascularization in Lower-Extremity PAD Patients
A twice-daily regimen of 2.5 mg of rivaroxaban plus aspirin significantly reduced lower limb and cardiovascular adverse events in comparison with placebo in patients who underwent revascularization for lower-extremity peripheral artery disease (PAD), according to late-breaking trial results presented Saturday at the American College of Cardiology Scientific Sessions 2020 virtual conference.